en | fr | de | sp | it | du | ru | pr
HONcode status
Certificate of compliance with the Code of Conduct HONcode

HONcode status The health Website
is in compliance with the HONcode

Title of the site:Palliativedrugs.com
Web address:http://www.palliativedrugs.com/
HONcode PIN number :HONConduct825189
Date of initial review: 02 Nov 2000
Validity of certificate20 Jul 2011 - Jul 2013
Date of last visit25 Feb 2014
   Show the HONcode seal on this site

This certificate confirms the revision of the site by the HONcode Team at the above date.
It respects and pledges to honor the 8 principles of the HON Code of Conduct (HONcode).

* 1. Authoritative   2. Complementarity   3. Privacy   4. Attribution   5. Justifiability   6. Transparency
    7. Financial disclosure   8. Advertising policy

HONcode status
HONcode status

Follow us on
Follow me on Twitter  Find us on Facebook


Speed access of ethical health information online is critical.

Help us in our mission:

Do you think the site is not respecting the HONcode? Do not hesitate to report a claim on this site

The Health on the Net (HON) certificate serves as a guarantee that this website, at the date of its certification, complies with and pledges to honor the 8 principles of the HON Code of Conduct as drawn up by the HON foundation.

The responsible of the certified site commits to keep the site in compliance with the HON code principles for the duration of the certification.

Although measures such as a complaint mechanism, the periodical review and the automatic surveillance mechanisms are put in place to guarantee the compliance of the certified website with the ethical principles of HON as much as possible, incidental inaccuracies cannot be completely excluded. In no event the HON foundation and/or its partner(s) can be held liable for any damages resulting from the use or inability to use HON certified websites nor can the HON foundation and/or its partner(s) be held liable for the content of these certified websites, including, but not limited to the information of third-parties or hyperlinks accessible via HON certified websites.

The certified website is responsible for the content of its website, unless otherwise provided by law.


>> More information about the HONcode?

You will find below the elements identified by the HONcode team at a precise date to justify the respect of the 8 ethical principles.

The content of this certificate has been collected and written by the Health On the Net Foundation (HON) and should not be used without previous permission granted by HON. A request for permission can be sent to: HON.

1. Information must be authoritative
Robert Twycross DM Oxon, FRCP London is Emeritus Clinical Reader in Palliative Medicine, Oxford University, former Head, WHO Collaborating Centre for Palliative Care, and Director, palliativedrugs.com Ltd. He has written some 300 articles, chapters and editorials, and is the author of several books, notably Pain Relief in Advanced Cancer. Churchill Livingstone, Edinburgh 1994; Symptom Management in Advanced Cancer (3nd edition, with Andrew Wilcock). Radcliffe Medical Press, Oxon, 2001; and Introducing Palliative Care (4th edition). Radcliffe Medical Press, Oxon 2003. He...
  (14 Jul 2011) - Link

For the collaborative platform:
Your message will not be displayed until it has been screened by palliativedrugs.com staff, this will usually occur within 24h. Once it has been accepted, it will be displayed on the bulletin board and e-mailed in a digest to registered users. However, not all messages are approved; reasons for not posting include:
the topic has come up before with no apparent attempt to search the bulletin board
the information is accessible in the formulary section of the website with no apparent attempt to access this
blanket requests with no apparent attempt to answer their own question, e.g. "I am doing a project on pain, please help"
use of trade rather than generic/recognised international names (rINNs) for drugs or unfamiliar abbreviations
personal messages.
At the discretion of palliativedrugs.com staff, a posting may be allowed on the board, but will not be circulated.

We reserve the right to prevent messages which are not sent in a professional, courteous and supportive manner from being posted to the board (see Terms and conditions).
(20 Jul 2011) - Link

2. Presentation of the site
in order to promote and disseminate information about the use of drugs in palliative care (...)

  (14 Jul 2011) - Link

For the collaborative platform:

This bulletin board was initially set up to facilitate the exchange of information on matters relating to drug and symptom control in palliative care between colleagues. Non-drug and service issues are now also welcomed.
(20 Jul 2011) - Link

Our site is intended for health professionals who require access to the information on it for their professional or educational work.
  (14 Jul 2011) - Link

Purpose of the website
Information on our site is not suitable for diagnosis, self-diagnoses or dispensing without expert evaluation of the information on which you are relying.
  (14 Jul 2011) - Link

3. Confidentiality
Information we may collect from you

We may collect and process the following data about you:

* information that you provide by filling in forms on our site http://www.palliativedrugs.com (“our site”). This includes information provided at the time of registering to use our site, posting material or requesting further services, and includes your name, profession, work address, telephone number, and e-mail address. We may also ask you for information when you complete surveys, and when you report a prob...
  (14 Jul 2011) - Link

For the collaborative platform:

Once posted and approved, the messages will be visible to all registered members and cannot be edited or removed.
(26 Jul 2011) - Link

4. Information must be documented: Referenced and dated
Only data for one sample are displayed among those selected.
Palexia SPC
Palexia SR SPC
SMC advice
  (20 Jul 2011) - Link

For the collaborative platform:

Supporting references are also encouraged when the advice given is not based on personal experience.
(26 Jul 2011) - Link

7th July 2011
  (20 Jul 2011) - Link

For the collaborative platform:

Date: July 13, 2011 12:35AM
(20 Jul 2011) - Link

5. Justification of claims
Its use is restricted to patients in whom morphine sulphate modified-release has failed to provide adequate pain control or is not tolerated. The SMC has not yet received a submission for tapentadol immediate-release tablets and theses are therefore currently not recommended for use in NHS Scotland.
  (20 Jul 2011) - Link

For the collaborative platform:

A contribution must:
* be accurate (where it states facts);
* be genuinely held (where it states opinions);
* comply with the law applicable in England and Wales and in any country from which it is posted; and
* be relevant.
(20 Jul 2011) - Link

6. User support and adequation
  (14 Jul 2011) - Link

  (14 Jul 2011) - Link

7. Disclosure of funding sources
Our income is derived from sales of the Palliative Care Formulary books and market research. Profits from the company will be used to fund research and education initiatives in Palliative care emanating from Oxford and Nottingham.
  (14 Jul 2011) - Link

For the collaborative platform:

palliativedrugs.com staff
(20 Jul 2011) - Link

8. Advertising policy
We do not host commercial advertisements.
  (14 Jul 2011) - Link

For the collaborative platform:

A contribution must not: contain any advertising or promote any services or web links to other sites.
(20 Jul 2011) - Link

HONcode status

You have your own website ? Ask for the certification!

Download the free HONcode Toolbar! Search to the HON database of certified websites.
Download the free HONcode Toolbar: Automatic verification of the certification status of health/medical websites.

Principles Search HONcode sites © Health On the Net Foundation